

PUBLIC SUMMARY DOCUMENT

Product: Dansac NovaLife 2 Convex GX+ Wafer

Applicant: Dansac

Date of SPAP Meeting: 12 October 2021

1. Proposed Deletion on the Stoma Appliance Scheme

The applicant, Dansac, sought the deletion of one variant from Dansac NovaLife 2 Convex GX+ Wafer (SAS Code 80050E) in subgroup 4(c) of the Stoma Appliance Scheme (the Scheme) Schedule, due to the variant being discontinued. The product, including 10 variants, is currently listed at a unit price of \$5.84, with a maximum monthly quantity of 20 units.

2. Substitute products

The nominated substitute product is a variant of Dansac NovaLife TRE Convex Baseplate (SAS Code 80202E) in the same subgroup. The product, including eight variants, is currently listed at a unit price of \$5.84, with a maximum monthly quantity of 20 units.

Variant to be deleted

Product Code	Description
2055-40	no belt loops, mechanical coupling, 55mm ring, floating flange, 1.2mm, hydrocolloid baseplate, medium convexity, firm baseplate material, hydrocolloid self-adhesive, standard wear, oval, pre-cut, 40mm, release tabs,

Nominated substitute – SAS Code 80202E

Product Code	Description
3255-40	belt loops on each side of pouch, mechanical coupling, 55mm ring, floating flange, 0.7mm, hydrocolloid baseplate, medium convexity, rigid convexity, hydrocolloid self-adhesive, standard wear, oval, pre-cut, 40mm, release tabs,

3. Background

This product was first listed on the Scheme Schedule on 1 April 2016.

4. Clinical Place for the Product

The proposed substitute product provides an alternative for users requiring a two-piece baseplate pouch with convex mechanical coupling.

Financial Analysis

The substitute product is currently listed in subgroup 4(c) of the Scheme Schedule at the same cost and maximum monthly quantity. It is therefore, unlikely that there would be any budgetary impact for the Scheme as a consequence of deleting one variant.

5. Panel Recommendation

The Panel recommended the deletion of one variant of Dansac NovaLife 2 Convex GX+ Wafer (SAS Code 80050E) in subgroup 4(c) of the Scheme Schedule at the unit price of \$5.84, with a maximum monthly quantity of 20 units.

The Panel also noted that Dansac is to advise Stoma Associations, ostomates, Stomal Therapy Nurses and ACSA of the deletion. A period of approximately six months from the date of the Panel's recommendation (12 October 2021) should be given to allow users of the variant to seek a suitable alternative and to enable Stoma Associations to manage their stock levels.

6. Context for Decision

The Panel helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. A Panel decision not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. A company can resubmit to the Panel following a decision not to recommend listing or changes to a listing. The Panel is an advisory committee and as such its recommendations are non-binding on Government. All Panel recommendations are subject to Cabinet/Ministerial approval.

7. Applicant's Comment

Dansac agrees with the SPAP recommendation.